top of page

PROGRAMME   EHMSG Workshop

Friday, September 13, 2024

 

08.25 – 08.30 hrs | Welcome by EHMSG President José Machado

08.30 – 10.30 hrs | Session 1:  Hot topics in H.pylori and gut microbiota

Chair: Jose Machado, Porto, Portugal & Ari Ristimäki, Helsinki, Finland

08.30 – 08.50 hrs                

1.1. The person-to-person transmission landscape of the gut and oral microbiomes

Vitor Heidrich, Italy

08.50 – 09.10 hrs                

1.2. New drugs targeting H. pylori envelopes

Ivo Boneca, France

09.10 – 09.30 hrs                

1.3. Evolving concepts in H. pylori management

Shailja Shah, United States

09.30 – 09.50 hrs                

1.4. Vaccination Protects Against Gastric Cancer

Thomas Boren, Umea, Sweden

09.50 – 10.10 hrs                

1.5. The humanized Leb mouse model reproduces the Correa gastric cancer cascade during the chronic H. pylori infection

Artem Piddubnyi, Umea, Sweden

10.10 – 10.30 hrs                

1.6. GWAS on H. pylori seroprevalence

Constanza Camargo, Rockville, MD, United States

10.30 – 11.00 hrs | Coffee Break

 

11.00 – 12.45 hrs | Session 2: News on gastritis (Parallel Session)

Chair: Theodore Rokkas, Athens, Greece & Fatima Carneiro, Porto, Portugal

 

11.00 – 11.20 hrs                

02.01 The RE.GA.IN consensus project

Massimo Rugge, Italy

11.20 – 11.40 hrs                

02.02 Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients

Ludovica Bricca, Italy

11.40 – 12.00 hrs                

02.03 Trends in the prevalence of atrophic gastritis and Helicobacter pylori in Far East

Yoshio Yamaoka, Japan

12.00 – 12.15 hrs                

02.04 Helicobacter pylori Seroprevalence In Histologically H. pylori-Negative Autoimmune Atrophic Gastritis Patients

Edith Lahner, Rome, Italy

12.15 – 12.30 hrs                

02.05. Interleukin‐27 Is Highly Expressed In The Serum And Gastric Mucosa Of Children With H. pylori‐Associated Gastroduodenal Diseases

Dulciene Queiroz, Belo Horizonte, Brasil

12.30 – 12.45 hrs                

02.06 Autoimmune Gastritis In Pediatric Age And Its Relationship With H. pylori Infection

Inês Aires Martins, Porto, Portugal

 

11.00 – 12.45 hrs |Session 3: Microbiome mechanisms of action (Parallel Session)

​Chair: Mirjana Rajilic-Stojanovic, Belgrade, Serbia & Rui Ferreira, Porto, Portugal

11.00 – 11.20 hrs                

03.01 Protein fermentation products and health outcomes

Silvio Waschina, Kiel, Germany

11.20 – 11.40 hrs                

03.02 Mechanisms of microbiome engraftment

Gianluca Ianiro, Italy

11.40 – 12.00 hrs                

03.03 Mycobiome in IBD

Petra Bacher, Germany

12.00 – 12.15 hrs                

03.04 Microbiome Composition In Patients With Upper Gastrointestinal Cancer And Small Intestinal Bacterial Overgrowth (SIBO)

Marino Venerito, Magdeburg, Germany

12.15 – 12.30 hrs                

03.05. The Impacts Of The Crosstalk Between Bacterial Vaginosis Associated Bacteria And Trichomonas Vaginalis On The Pathogenesis And Host Immune Responses

Shu-Fang Chiu, Taipei, Taiwan

12.30 – 12.45 hrs                

03.06 Mycobiome Dysbiosis In Liver Cirrhosis Patients

Darja Nikitina, Kaunas, Lithuania

 

12.45 – 14.00 hrs | Lunch Break & Poster Viewing

 

14.00 – 15.00 hrs | Session 4: Industry-Sponsored Satellite Symposium

Chair: Colm O’Morain, Dublin, Ireland & Peter Malfertheiner, Munich, Germany

Click HERE for details

15.00 – 16.45 hrs | Session 5: Helicobacter pylori: Genetics and Beyond (Parallel Session)

​Chair: Peter Malfertheiner, Munich, Germany & Celso Reis, Porto, Portugal

15.00 – 15.20 hrs                

05.01 Differences in H. pylori population structures worldwide

Kaisa Thorell, Sweden

15.20 – 15.40 hrs                

05.02  H. pylori evolution depends on niche specific physiological conditions

Sebastian Suerbaum, Germany

15.40 – 16.00 hrs                

05.03 Impact of H. pylori on mucosal immunity and colorectal cancer

Markus Gerhard, Germany

 

16.00 – 16.15 hrs                

05.04 Helicobacter pylori Infection Leads To Systemic Metabolic Reprogramming Through The Il-6/JAK/STAT3 Pathway

Bingting Yu, Rotterdam, Netherlands

16.15 – 16.30 hrs                

05.05 The H. pylori Autotransporter ImaA Associates With Extracellular Vesicles To Modulate Host Inflammatory Responses In Gastric Epithelial Cells

Angus Cramond, Clayton, Australia

16.30 – 16.45 hrs                

05.06 The Prophages Of The Helicobacter Genus

Filipa Vale, Lisbon, Portugal

 

15.00 – 16.45 hrs | Session 6: Oncobiome (Parallel Session)

Chair: Juozas Kupcinskas, Kaunas, Lithuania & Carina Pereira, Porto, Portugal

                                            

15.00 – 15.20 hrs                

06.01 Microbiome mediated inflammation in colon cancer

Mathias Chamaillard, Lille, France

15.20 – 15.40 hrs                

06.02 Predicting CRC survival post-surgical resection using tumour microbial profiling

James Alexander, United Kingdom

15.40 – 16.00 hrs                

06.03 Microbiota-modulated immune checkpoint

Carolina Alves Costa Silva, France

16.00 – 16.15 hrs                

06.04 Longitudinal Definition Of The Gastric Microbiome From A High-Gastric-Cancer-Risk Cohort From Colombia, South America

Anthony Mannion, United States

16.15 – 16.30 hrs                

06.05 Characterization Of The Intratumoral Microbiota In Gastric Cancer Patients

Marine Jauvain, Bordeaux, France

16.30 – 16.45 hrs                

06.06 Microbiome-Derived Metabolites As Novel Biomarkers Of Gastric Cancer

Rui Ferreira, Porto, Portugal

 

16.45 – 17.15 hrs | Coffee Break

 

17.15 – 19.00 hrs | Session 7: Gastric Carcinogenesis (Parallel Session)

​Chair: Emilie Bessède, Bordeaux, France & Carla Oliveira, Porto, Portugal

17.15 – 17.35 hrs                

07.01 Microbiome and gastric cancer

Ceu Figueiredo, Portugal

 

17.35 – 17.55 hrs                

07.02 Gastric Intestinal Metaplasia an Innocent Bystander in Gastric Cancer?

Ken Sugano, Japan

17.55 – 18.15 hrs                

07.03 Natural History of Sporadic and Hereditary Diffuse Gastric Carcinoma: From Onset to Progression

Fatima Carneiro, Portugal

 

18.15 – 18.30 hrs                

07.04 Unveiling Plasma Protein Signatures For Gastric Preneoplasia And Cancer Lesion Detection

Eliette Touati, Paris, France

18.30 – 18.45 hrs                

07.05 Gastric Cancer Invasion: Physical And Biochemical Nuclear Readouts Elicited By E-Cadherin Loss

Joana Figueiredo, Porto, Portugal

18.45 – 19.00 hrs                

07.06 The Autophagy Protein IRGM Is A Key Player In Gastric Carcinogenesis

Elsa Kalluzhathil, Kensington, Australia

 

17.15 – 19.00 hrs | Session 8: FMT Session (Parallel Session)

​Chair: Josbert Keller, Den Haag, Netherlands & Gianluca Ianiro, Rome, Italy

17.15 – 17.35 hrs                

08.01 Safety in FMT

Josbert Keller, Netherlands

17.35 – 17.55 hrs                

08.02 Regulation of FMT and donor screening

Christian Hvas, Denmark

                                            

17.55 – 18.15 hrs                

08.03 How to improve FMT success

Alexander Link, Germany

 

15.15 – 18.30 hrs                

08.04 Effectiveness Of Fecal Microbiota Transplant In Metabolic Syndrome:  A Randomized Double-Blinded Placebo-Controlled Trial

Ratha-korn Vilaichone, Pathumthani,Thailand

18.30 – 18.45 hrs                

08.05 Fecal Microbiota Transplantation (FMT) Versus Placebo In Patients Receiving Pembrolizumab Plus Axitinib For Advanced Renal Cell Carcinoma. A Double-Blind Randomized Controlled Trial (TACITO Trial)

Gianluca Ianiro, Rome, Italy

18.45 – 19.00 hrs                

08.06 Efficacy And Safety Of Fecal Microbiota Transplantation In Patients With Irritable Bowel Syndrome: A Preliminary Report

Ho-Kyoung Lee, Seoul, Republic of Korea

 

20.00 hrs                             

EHMSG Conference Dinner


 

Saturday, September 14, 2024

 

08.30 – 09.15 hrs | Session 9: Memorial Talks

Chair: Francis Mégraud, Bordeaux, France & Colm O’Morain, Dublin, Ireland & Peter Malfertheiner, Munich, Germany

08.30 – 08.45 hrs                 

09.01 In Memoriam Ashley Price

Anthony Axon, United Kingdom

                                            

08.45 – 09.00 hrs                

09.02 In Memoriam Pentti Sipponen

Ari Ristimäki, Finland

 

09.00 – 09.15 hrs                

09.03 In Memoriam Adrian Lee

Jim Fox, United States

09.15 – 11.00 hrs | Session 10: H. pylori management (Parallel Session)

​Chair: Colm O’Morain, Dublin, Ireland & Nuno Almeida, Coimbra, Portugal

09.15 – 09.35 hrs                

10.01 Current role of tailored therapy in treating H. pylori infection

Theodore Rokkas, Greece

09.35 – 09.55 hrs                

10.02 The rebirth of Bismuth in H. pylori eradication

Rocco Maurizio Zagari, Italy

09.55 – 10.15 hrs                

10.03 Latin American Registry on the Management of H. pylori Infection (Hp-LATAMReg)

Arnoldo Riquelme, Chile 

10.15 – 10.30 hrs                

10.04 Effectiveness And Safety Of First-Line Empirical Non-Bismuth Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapies In Spain: Analysis Of 12,000 Patients From The European Registry On Helicobacter pylori Management (Hp-Eureg)

Olga Nyssen, Madrid, Spain

10.30 – 10.45 hrs                

10.05 A Novel Multi-Epitope-Based Vaccine Against H. pylori; Evaluation Of The Protective Effect
Behnam Kalali, Munich, Germany

10.45 – 11.00 hrs                

10.06 7-Day Therapy Vs. 14-Day Therapy In Empirical And Tailored Therapy: A Placebo-Controlled Randomized Nationwide Trial In Korea

Byung-Wook Kim, Incheon, Republic of Korea

09.15 – 11.00 hrs | Session 11: Probiotics (Parallel Session)

​Chair: Francesco Franceschi, Rome, Italy & Christian Schulz, Munich, Germany

09.15 – 09.35 hrs                

11.01 Use of probiotics in chronic liver diseases

Alexander Link, Germany

09.35 – 09.55 hrs                

11.02 Inflammatory bowel diseases: when can probiotics be helpful?

Loris Lopetuso, Italy

09.55 – 10.15 hrs                

11.03 Dietary Sulforaphane Increases Butyrate-Producing Intestinal Microbiota And Decreases Fecal Calprotectin Level In Patients With Ulcerative Colitis

Akinori Yanaka, Tsukuba, Japan

10.15 – 10.30 hrs                

11.04 The Beneficial Effect Of A Probiotic Intervention On Quality Of Sleep - A Randomized, Double-Blinded, Placebo-Controlled Study

Angela Horvath, Graz, Austria

10.30 – 10.45 hrs                

11.05 Bifidobacterium Modulates The Immune Response In A Microsatellite Instability Colorectal Cancer Mouse Model

Patricia Vieira, Porto, Portugal

10.45 – 11.00 hrs                

11.06 Bacterial Genotoxins Trigger Invadosome Formation Associated To Matrix Degradation

Lamia Azzi-Martin, Bordeaux, France

11.00 – 11.30 hrs | Coffee Break

 

11.30 – 13.30 hrs | Session 12: Debates – Gastric cancer screening

​Chair: Marcis Leja, Riga, Latvia & Miguel Areia, Coimbra, Portugal

11.30 – 11.50 hrs                

12.01 Optimal strategies for gastric cancer screening – targeted vs. population based

Iris Lansdorp Vogelaar, Netherlands

11.50 – 12.10 hrs                

12.02 What is the optimal age for screening?

Jan Bornschein, United Kingdom

12.10 – 12.30 hrs                

12.03 Is there a role for endoscopy and AI in gastric cancer screening

Mario Dinis Ribeiro, Portugal

12.30 – 12.50 hrs                

12.04 Gastric cancer screening experience in Japan

Hidekazu Suzuki , Japan

12.50 – 13.10 hrs                

12.05 Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A                     Nationwide Cohort Study

Hae Won Yoo, Korea

13.10 – 13.30 hrs                

12.06 Helicobacter pylori treatment and risk of gastric cancer in large intervention trials in China

Wen Qing Li, China

13.30 – 15.00 hrs | Lunch Break & Poster Viewing

 

15.00 – 17.00 hrs |Session 13: Updates in Helicobacter & Microbiota

​Chair: Annemieke Smet, Antwerp, Belgium & Ceu Figueiredo, Porto, Portugal

15.00 – 15.20 hrs                

13.01 Million Microbiome from Humans Project

Lars Engstrand, Sweden

15.20 – 15.40 hrs                

13.02 Cortactin-dependent control of Par1b-regulated epithelial cell polarity in Helicobacter pylori Infection

Steffen Backert, Erlangen, Germany

15.40 – 16.00 hrs                

13.03 Effect of faecal microbiota transplantation on multidrug-resistant bacteria and the resistome

Elizabeth Terveer, The Netherlands

16.00 – 16.20 hrs                

13.04 The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection

Cristina Martins, Portugal

16.20 – 16.40 hrs                

13.05 Novel principles for cure of H. pylori infection

Peter Malfertheiner, Germany

16.40 – 17.00 hrs                

13.06 Histamine Signaling Is Essential for Tissue Macrophage Differentiation and Suppression of Bacterial Overgrowth in the Stomach Cell

Ki Taek Nam, Korea

      

17.00 – 18.00 hrs | Session 14: Closing Session

​Chair: José Machado, Porto, Portugal & Francis Mégraud, Bordeaux, France

17.00 – 17.20 hrs                

14.01 Awarding of the Marshall and Warren Medal 2024 to Fatima Carneiro, Porto, Portugal

17.20 – 17.35 hrs

14.02 Awarding of the EHMSG Oral and Poster Awards

17.35 – 17.50 hrs

14.03 Presentation of the EHMSG Journal

Francesco Franceschi, Italy

17.50 – 18.00 hrs                

14.04 Presentation of the next meeting in Rome, Italy

Gianluca Ianiro, Italy

Closing Remarks

© 2025 EHMSG

The EHMSG is a member of the United European Gastroenterology, a professional non-profit organisation combining all the leading European societies concerned with digestive disease.
UEG represents over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

ueglogomember.jpg
  • Twitter
bottom of page